wikidoc - Recent changes [en]

Sandbox

2026-04-28T00:07:58Z

Multidisciplinary Aortic Team and Shared Decision-Making[2]

Datopotamab deruxtecan-dlnk

2026-04-27T23:52:27Z

Sandbox

2026-04-27T23:15:44Z

Show changes

Atrial fibrillation

2026-04-27T21:51:47Z

Rhythm Control

Show changes

User:Hasnain Ali

2026-04-27T20:24:40Z

← Older revision		Revision as of 20:24, 27 April 2026
Line 10:		Line 10:
	I create original content on my areas of interest and refresh older chapters to keep the medical information current.		I create original content on my areas of interest and refresh older chapters to keep the medical information current.

	* Resident ~~Medical Officer with Dept. of Neurology~~, Liaquat University hospital Hyderabad/Jamshoro, Pakistan.		* Resident, Liaquat University hospital Hyderabad/Jamshoro, Pakistan.

	I provide inpatient and outpatient neurological care, managing up to 5 inpatients daily and around 30 clinic and emergency patients per week. Alongside clinical duties, I participated in multidisciplinary academic activities and contributed to research through systematic data collection and documentation.		I provide inpatient and outpatient neurological care, managing up to 5 inpatients daily and around 30 clinic and emergency patients per week. Alongside clinical duties, I participated in multidisciplinary academic activities and contributed to research through systematic data collection and documentation.

Industrial and organizational psychology

2026-04-27T20:07:19Z

Career calling

← Older revision		Revision as of 20:07, 27 April 2026
(4 intermediate revisions by the same user not shown)
Line 18:		Line 18:
	* [[Empowerment(psychology)\|Empowerment]]		* [[Empowerment(psychology)\|Empowerment]]
	* [[Engagement (psychology)\|Engagement]]		* [[Engagement (psychology)\|Engagement]]
			* [[Career calling]]
	* [[Job satisfaction]]		* [[Job satisfaction]]
	* [[Burnout (psychology)\|Burnout]]		* [[Burnout (psychology)\|Burnout]]
Line 63:		Line 64:
	* "Would you say you are thriving or struggling with the following types of bonds or relationships at work?"		* "Would you say you are thriving or struggling with the following types of bonds or relationships at work?"

	A separate body of research has emerged more recently that gives a broader definition to thriving, but does not cite the above research that has used factor analysis to identify core features~~<ref>~~<ref name="pmid28913621">{{cite journal\| author=Brady KJS, Trockel MT, Khan CT, Raj KS, Murphy ML, Bohman B et al.\| title=What Do We Mean by Physician Wellness? A Systematic Review of Its Definition and Measurement. \| journal=Acad Psychiatry \| = 2017 \| volume= \| issue= \| pages= \| pmid=28913621 \| doi=10.1007/s40596-017-0781-6 \| pmc= \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28913621 }} </ref><ref>Feeney, B. C., & Collins, N. L. (2015). A new look at social support: A theoretical perspective on thriving through relationships. Personality and Social Psychology Review, 19(2), 113-147. {{doi\|10.1177/1088868314544222}}</ref>.		A separate body of research has emerged more recently that gives a broader definition to thriving, but does not cite the above research that has used factor analysis to identify core features<ref name="pmid28913621">{{cite journal\| author=Brady KJS, Trockel MT, Khan CT, Raj KS, Murphy ML, Bohman B et al.\| title=What Do We Mean by Physician Wellness? A Systematic Review of Its Definition and Measurement. \| journal=Acad Psychiatry \| = 2017 \| volume= \| issue= \| pages= \| pmid=28913621 \| doi=10.1007/s40596-017-0781-6 \| pmc= \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28913621 }} </ref><ref>Feeney, B. C., & Collins, N. L. (2015). A new look at social support: A theoretical perspective on thriving through relationships. Personality and Social Psychology Review, 19(2), 113-147. {{doi\|10.1177/1088868314544222}}</ref>.

	==== Importance====		==== Importance====
Line 177:		Line 178:
	* Emotional: I feel energetic at my job; I am enthusiastic in my job		* Emotional: I feel energetic at my job; I am enthusiastic in my job
	* Cognitive: At work, I focus a great deal of attention on my job; At work, I am absorbed by my job		* Cognitive: At work, I focus a great deal of attention on my job; At work, I am absorbed by my job

			===Career calling ===
			Career calling has various definitions, a more recent definition by Rosso and Wrzesniewski is, "meaningful beckoning toward work activities that are morally, socially, and personally significant"<ref name="Rosso2010">{{cite journal \| last1=Rosso \| first1=Brent D. \| last2=Dekas \| first2=Kathryn H. \| last3=Wrzesniewski \| first3=Amy \| title=On the meaning of work: A theoretical integration and review \| journal=Research in Organizational Behavior \| volume=30 \| date=2010 \| doi=10.1016/j.riob.2010.09.001 \| pages=91–127 \| url=https://linkinghub.elsevier.com/retrieve/pii/S0191308510000067 \| access-date=2026-04-27}}</ref>. calling can be measured with<ref name="Dik2012">{{cite journal \| last1=Dik \| first1=Bryan J. \| last2=Eldridge \| first2=Brandy M. \| last3=Steger \| first3=Michael F. \| last4=Duffy \| first4=Ryan D. \| title=Development and Validation of the Calling and Vocation Questionnaire (CVQ) and Brief Calling Scale (BCS) \| journal=Journal of Career Assessment \| volume=20 \| issue=3 \| date=2012 \| issn=1069-0727 \| doi=10.1177/1069072711434410 \| pages=242–263 \| url=https://journals.sagepub.com/doi/10.1177/1069072711434410 \| access-date=2026-04-27}}</ref>:
			# I have a calling to my current line of work.
			# I have a good understanding of my calling as it applies to my career.

			Career calling can be promoted by a career calling climate at work<ref name="Chen 2025">{{cite journal \| last1=Chen \| first1=Jiatian \| last2=May \| first2=Douglas R. \| last3=Schwoerer \| first3=Catherine E. \| title=Career calling climate: The development and validation of a scale for a new construct \| journal=Journal of Management & Organization \| volume=31 \| issue=4 \| date=2025 \| issn=1833-3672 \| doi=10.1017/jmo.2023.16 \| pages=1688–1707 \| url=https://www.cambridge.org/core/product/identifier/S1833367223000160/type/journal_article \| access-date=2026-04-27}}</ref>.

			Calling may increase engagement at work, especially is organizational commitment is present<ref name="Cao2019">{{cite journal \| last1=Cao \| first1=Yudi \| last2=Liu \| first2=Jingying \| last3=Liu \| first3=Kejia \| last4=Yang \| first4=Mengyu \| last5=Liu \| first5=Yanhui \| title=The mediating role of organizational commitment between calling and work engagement of nurses: A cross-sectional study \| journal=International Journal of Nursing Sciences \| volume=6 \| issue=3 \| date=2019-07-10 \| issn=2352-0132 \| pmid=31508452 \| pmc=6722477 \| doi=10.1016/j.ijnss.2019.05.004 \| pages=309–314 \| url=https://pubmed.ncbi.nlm.nih.gov/31508452 \| access-date=2026-04-27}}</ref> as measured by the organizational commitment scale (OCS)<ref name="Allen2011">{{cite journal \| last1=Allen \| first1=Natalie J. \| last2=Meyer \| first2=John P. \| title=The measurement and antecedents of affective, continuance and normative commitment to the organization \| journal=Journal of Occupational Psychology \| volume=63 \| issue=1 \| date=1990 \| issn=0305-8107 \| doi=10.1111/j.2044-8325.1990.tb00506.x \| pages=1–18 \| url=https://bpspsychub.onlinelibrary.wiley.com/doi/10.1111/j.2044-8325.1990.tb00506.x \| access-date=2026-04-27}}</ref>.

	===Satisfaction===		===Satisfaction===

TC element gene transcriptions

2026-04-27T19:03:53Z

GT box (Sato) samplings

← Older revision		Revision as of 19:03, 27 April 2026
Line 215:		Line 215:

	==GT box (Sato) samplings==		==GT box (Sato) samplings==
			[[TC element gene transcriptions#GT box (Sato) samplings\|GT box (Sato) samplings]]

	Copying the apparent consensus sequence for the RCE, GT box, (GGGGTGGGG) and putting it in "⌘F" finds none located between ZSCAN22 or between ZNF497 and A1BG as can be found by the computer programs. However, RCE (GGGGAGGGG) finds none located between ZSCAN22 and one between ZNF497 and A1BG.		Copying the apparent consensus sequence for the RCE, GT box, (GGGGTGGGG) and putting it in "⌘F" finds none located between ZSCAN22 or between ZNF497 and A1BG as can be found by the computer programs. However, RCE (GGGGAGGGG) finds none located between ZSCAN22 and one between ZNF497 and A1BG.

Atrial fibrillation overview

2026-04-27T17:15:33Z

Show changes

Supraventricular tachycardia

2026-04-27T17:08:57Z

Show changes

TC element gene transcriptions

2026-04-26T23:40:17Z

GT box (Motojima) samplings

← Older revision		Revision as of 23:40, 26 April 2026
Line 302:		Line 302:
	==GT box (Motojima) samplings==		==GT box (Motojima) samplings==
	{{main\|Model samplings}}		{{main\|Model samplings}}
			[[TC element gene transcriptions#GT box (Motojima) samplings\|GT box (Motojima) samplings]]

	Copying the apparent consensus sequence for the GT box (TGGGTGGGGCT) and putting it in "⌘F" finds none located between ZSCAN22 or between ZNF497 and A1BG as can be found by the computer programs.		Copying the apparent consensus sequence for the GT box (TGGGTGGGGCT) and putting it in "⌘F" finds none located between ZSCAN22 or between ZNF497 and A1BG as can be found by the computer programs.

Rgt1p gene transcriptions

2026-04-26T09:27:38Z

RGT samplings

← Older revision		Revision as of 09:27, 26 April 2026
Line 45:		Line 45:

	==RGT samplings==		==RGT samplings==
			[[Rgt1p gene transcriptions#RGT samplings\|RGT samplings]]

	Copying a responsive elements consensus sequence CGGAACTA or CGGGACTT and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence CGGAACTA or CGGGACTT and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.

GLM box gene transcriptions

2026-04-26T05:58:03Z

GLM box sampling of A1BG promoters

← Older revision		Revision as of 05:58, 26 April 2026
Line 28:		Line 28:

	==GLM box sampling of A1BG promoters==		==GLM box sampling of A1BG promoters==
			[[GLM box gene transcriptions#GLM box sampling of A1BG promoters\|GLM box sampling of A1BG promoters]]

	For the Basic programs (starting with SuccessablesGLM.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), including extending the number of nts from 958 to 4445, the programs are, are looking for, and found:		For the Basic programs (starting with SuccessablesGLM.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), including extending the number of nts from 958 to 4445, the programs are, are looking for, and found:

Chronic stable angina overview

2026-04-25T15:44:25Z

Treatment

Show changes

Cardiomyopathy overview

2026-04-25T14:08:19Z

← Older revision		Revision as of 14:08, 25 April 2026
(15 intermediate revisions by the same user not shown)
Line 1:		Line 1:
	__NOTOC__		__NOTOC__
	{{Cardiomyopathy}}		{{Cardiomyopathy}}
	{{CMG}}; {{AE}} {{EdzelCo}}		{{CMG}}; {{AE}} {{EdzelCo}} {{MSD}}

	==Overview==		==Overview==
Line 29:		Line 29:
	==Treatment==		==Treatment==
	===Medical Therapy===		===Medical Therapy===
	Treatment ~~depends~~ on the ~~type~~ of cardiomyopathy, ~~but may include medication~~, ~~implanted [[artificial pacemaker\|pacemakers]]~~, ~~[[Implantable cardioverter~~-~~defibrillator~~\|~~defribillators]]~~, ~~or [[ventricular assist device]]s (LVADs)~~, ~~or [[ablation]]~~. ~~The goal of treatment is often~~ symptom relief, and ~~some~~ patients ~~may eventually require a [[~~heart transplant]]. ~~Treatment~~ of ~~cardiomyopathy (~~and ~~other heart diseases) using alternative methods such as [[stem cell therapy]] is commercially available but is not supported by convincing evidence~~.		Treatment is phenotype-directed and includes guideline-directed medical therapy (GDMT) for heart failure syndromes and targeted therapy for specific cardiomyopathies such as hypertrophic cardiomyopathy (HCM). In HCM, management includes symptom-directed pharmacotherapy (beta-blocker or nondihydropyridine calcium-channel blocker, with disopyramide or a cardiac myosin inhibitor in selected adults with obstructive physiology), risk-based use of ICDs, and septal reduction therapy at experienced centers when symptoms persist despite medical therapy.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref> <ref name="pmid35363499">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e895–e1032 \|date=May 2022 \|pmid=35363499 \|doi=10.1161/CIR.0000000000001063 \|url=}}</ref>For cardiomyopathy with HFrEF, foundational GDMT consists of an ARNI/ACE inhibitor/ARB, evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor, with additional therapies and device-based treatment individualized by EF, QRS, symptoms, and comorbidities.<ref name="pmid35363499">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e895–e1032 \|date=May 2022 \|pmid=35363499 \|doi=10.1161/CIR.0000000000001063 \|url=}}</ref> Goals include symptom relief, prevention of sudden cardiac death (when relevant, e.g., HCM), and modification of heart-failure trajectory; patients with advanced heart failure despite GDMT should be referred to an advanced HF team for consideration of transplant and/or durable mechanical circulatory support.<ref name="pmid35363500">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e876–e894 \|date=May 2022 \|pmid=35363500 \|doi=10.1161/CIR.0000000000001062 \|url=}}</ref> In HCM with atrial fibrillation, oral anticoagulation is recommended irrespective of CHA₂DS₂-VASc, and rhythm and/or rate control should be individualized.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref>

	===Surgery===		===Surgery===
	~~There~~ are ~~several types~~ of ~~surgery used~~ to ~~treat cardiomyopathy. They include~~ septal ablation, ~~[[septal myectomy]]~~, ~~surgically implanted devices to improve~~ the ~~function~~ of the ~~heart~~, ~~and [[heart transplant]]~~.		Procedural and surgical options are phenotype-specific and should be performed at experienced centers when indicated.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref> For symptomatic obstructive HCM refractory to medical therapy, septal reduction therapy includes surgical septal myectomy or (in selected patients) alcohol septal ablation. Advanced heart failure may require durable mechanical circulatory support and/or heart transplantation after evaluation by an advanced HF team.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref><ref name="pmid35363500">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e876–e894 \|date=May 2022 \|pmid=35363500 \|doi=10.1161/CIR.0000000000001062 \|url=}}</ref>

	===Primary Prevention===		===Primary Prevention===
	~~Methods of primary~~ prevention ~~for cardiomyopathy include; maintaining a healthy weight~~, ~~not smoking~~, ~~avoiding~~ alcohol and illicit drugs, ~~reducing stress~~, and ~~treating underlying conditions such as [[diabetes]] and [[high blood pressure]]~~.		Primary prevention focuses on ‘at risk’ (Stage A) and ‘pre-HF’ (Stage B) management: control hypertension, diabetes, obesity, and other cardiovascular risk factors; avoid cardiotoxins (including excess alcohol and illicit drugs); and treat structural heart disease early to prevent progression to symptomatic HF.<ref name="pmid35363500">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e876–e894 \|date=May 2022 \|pmid=35363500 \|doi=10.1161/CIR.0000000000001062 \|url=}}</ref><ref name="pmid38033089">{{cite journal \|vauthors=Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR \|title=2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=1 \|pages=e1–e156 \|date=January 2024 \|pmid=38033089 \|pmc=11095842 \|doi=10.1161/CIR.0000000000001193 \|url=}}</ref>

	==Preferences==		==Preferences==

GARE gene transcriptions

2026-04-25T08:37:54Z

GARE-like 2 samplings

← Older revision		Revision as of 08:37, 25 April 2026
(One intermediate revision by the same user not shown)
Line 232:		Line 232:

	==GARE-like 1 samplings==		==GARE-like 1 samplings==
			[[GARE gene transcriptions#GARE-like 1 samplings\|GARE-like 1 samplings]]

	Copying a responsive elements consensus sequence TAACA(A/G)A and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or one between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence TAACA(A/G)A and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or one between ZSCAN22 and A1BG as can be found by the computer programs.
Line 369:		Line 370:
	==GARE-like 2 samplings==		==GARE-like 2 samplings==
	{{main\|Model samplings}}		{{main\|Model samplings}}
			[[GARE gene transcriptions#GARE-like 2 samplings\|GARE-like 2 samplings]]

	Copying a responsive elements consensus sequence TAACGTA and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence TAACGTA and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.

GGC triplet gene transcriptions

2026-04-25T08:13:04Z

GGC samplings

← Older revision		Revision as of 08:13, 25 April 2026
Line 440:		Line 440:

	==GGC samplings==		==GGC samplings==
			[[GGC triplet gene transcriptions#GGC samplings\|GGC samplings]]

	Copying a responsive elements consensus sequence GGC and putting the sequence in "⌘F" finds 145 + 57 between ZNF497 and A1BG or 17 + 121 between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence GGC and putting the sequence in "⌘F" finds 145 + 57 between ZNF497 and A1BG or 17 + 121 between ZSCAN22 and A1BG as can be found by the computer programs.

Datopotamab deruxtecan-dlnk

2026-04-25T05:40:10Z

Show changes

Datopotamab deruxtecan-dlnk

2026-04-25T03:20:50Z

Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=DATROWAY |aOrAn=a |drugClass=Trop-2-directed antibody and topoisomerase inhibitor conjugate |indicationType=treatment |indication=DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: 1. Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastati..."

Show changes

GGC triplet gene transcriptions

2026-04-24T08:54:17Z

GGCGGC triplet samplings

← Older revision		Revision as of 08:54, 24 April 2026
Line 260:		Line 260:

	==GGCGGC triplet samplings==		==GGCGGC triplet samplings==
			[[GGC triplet gene transcriptions#GGCGGC triplet samplings\|GGCGGC triplet samplings]]

	# Negative strand, negative direction, looking for GGCGGC, 0.		# Negative strand, negative direction, looking for GGCGGC, 0.

← Older revision		Revision as of 23:52, 27 April 2026
Line 45:		Line 45:
	DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.		DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.

	Locally Advanced or Metastatic NSCLC		'''Locally Advanced or Metastatic NSCLC''

	In the pooled safety population of 484 patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01 ~~[see Adverse Reactions (6.1)]~~, ILD/pneumonitis occurred in 7% of patients treated with DATROWAY, including 0.6% of patients with Grade 3 and 0.4% with Grade 4. There were 8 (1.7%) fatal cases. The median time to onset for ILD was 1.4 months (range: 0.2 months to 9 months). Eleven patients (2.3%) had DATROWAY withheld and 20 patients (4.1%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 79% (26/33) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 45% of patients.		In the pooled safety population of 484 patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01, ILD/pneumonitis occurred in 7% of patients treated with DATROWAY, including 0.6% of patients with Grade 3 and 0.4% with Grade 4. There were 8 (1.7%) fatal cases. The median time to onset for ILD was 1.4 months (range: 0.2 months to 9 months). Eleven patients (2.3%) had DATROWAY withheld and 20 patients (4.1%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 79% (26/33) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 45% of patients.

	Unresectable or Metastatic Breast Cancer		Unresectable or Metastatic Breast Cancer
Line 86:		Line 86:


	The safety of DATROWAY was evaluated in 125 patients with EGFR-mutated NSCLC who received DATROWAY 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity in TROPION-Lung05 and TROPION-Lung01 ~~[see Clinical Studies (14.1)]~~ as well as TROPION-PanTumor01 (NCT03401385). Among these patients, the median duration of treatment was 6.1 months (range 0.7 months to 41.7 months).		The safety of DATROWAY was evaluated in 125 patients with EGFR-mutated NSCLC who received DATROWAY 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity in TROPION-Lung05 and TROPION-Lung01 as well as TROPION-PanTumor01 (NCT03401385). Among these patients, the median duration of treatment was 6.1 months (range 0.7 months to 41.7 months).

	The median age was 63 years (range: 36 to 81), 56% of patients were <65 years, 62% of patients were female; 66% were Asian, 26% were White, 0.8% were Black, 6% were other races; and 2.4% were of Hispanic ethnicity.		The median age was 63 years (range: 36 to 81), 56% of patients were <65 years, 62% of patients were female; 66% were Asian, 26% were White, 0.8% were Black, 6% were other races; and 2.4% were of Hispanic ethnicity.
Line 161:		Line 161:

	Reconstitute immediately before dilution.		Reconstitute immediately before dilution.
	More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted DATROWAY solution required, and the number of vial(s) of DATROWAY needed ~~[see Dosage and Administration (2.2)]~~.		More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted DATROWAY solution required, and the number of vial(s) of DATROWAY needed.
	Reconstitute each 100 mg vial using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection into each vial to obtain a final concentration of 20 mg/mL.		Reconstitute each 100 mg vial using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection into each vial to obtain a final concentration of 20 mg/mL.
	Swirl the vial gently until completely dissolved. Do not shake.		Swirl the vial gently until completely dissolved. Do not shake.
Line 286:		Line 286:
	Interstitial Lung Disease/Pneumonitis		Interstitial Lung Disease/Pneumonitis

	Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms ~~[see Warnings and Precautions (5.1)]~~.		Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms.
	Ocular Adverse Reactions		Ocular Adverse Reactions

	Inform patients about the need for eye exams at initiation and during treatment with DATROWAY ~~[see Dosage and Administration (2.3)]~~.		Inform patients about the need for eye exams at initiation and during treatment with DATROWAY .
	Advise patients to contact their healthcare provider if they experience any eye symptoms.		Advise patients to contact their healthcare provider if they experience any eye symptoms.
	Advise patients to use preservative-free lubricating eye drops several times daily and to avoid use of contact lenses during treatment with DATROWAY.		Advise patients to use preservative-free lubricating eye drops several times daily and to avoid use of contact lenses during treatment with DATROWAY.